Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Ongoing diarrhea is a common side effect of Mounjaro (tirzepatide), but skipping or delaying a dose on your own is generally not advised without guidance from your prescriber, since dose timing, hydration status, symptom severity, and whether you recently increased your dose all matter. Warning signs like diarrhea lasting more than a few days, blood in the stool, fever, severe abdominal pain, vomiting, dizziness, or signs of dehydration point toward contacting a clinician promptly rather than simply waiting for the next injection. There are several important factors, including timing rules for missed or late doses and when a dose reduction may be more appropriate than skipping, that you should review below before deciding.
Because diarrhea while on Mounjaro can stem from the medication, an infection, a food-related trigger, or another condition entirely, it helps to clarify what you are dealing with before changing your dose. Take a free, instant, online symptom check to better understand your symptoms and get a clearer sense of your next steps.
Last reviewed for medical accuracy: 09/13/2026
Should I Skip My Next Mounjaro Dose If I Still Have Diarrhea?
Starting Mounjaro (tirzepatide) can bring side effects, especially gastrointestinal ones like diarrhea. If you’ve experienced Mounjaro diarrhea after starting treatment, you’re not alone—many people notice changes in bowel habits during the first few weeks. Here’s what you need to know about managing diarrhea, when (and when not) to skip a dose, and how to get help if symptoms worsen.
Mounjaro activates receptors for two gut hormones (GLP-1 and GIP) to improve blood sugar control and support weight loss. Along the way, these hormones also:
Together, these effects can lead to loose stools or diarrhea, especially during the dose-titration period.
If diarrhea is mild, it typically settles as your body adjusts. Severe or persistent diarrhea requires more attention.
Skipping doses can reduce the effectiveness of Mounjaro and disrupt your treatment plan. As a general rule:
Always follow the titration schedule prescribed by your doctor or pharmacist. Do not make dose-timing decisions on your own if symptoms are more than mild.
Most cases of Mounjaro diarrhea after starting can be managed at home:
Stay Hydrated
Adjust Your Diet
Modify Timing
Over-the-Counter Remedies (if approved by your provider)
Monitor Symptoms
Speak to your doctor if you experience:
Your provider can assess whether you need to hold your next dose, adjust the titration schedule, or try alternative interventions.
If you’re unsure about how serious your symptoms are, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide whether to self-manage, consult your primary care provider, or seek urgent care.
Under guidance from your healthcare team, you may be advised to skip your next Mounjaro dose if:
Never skip doses impulsively. Unplanned dose interruptions can lead to fluctuating blood sugar levels or undermine long-term benefits.
Once diarrhea improves, work with your provider to prevent recurrence:
Mild diarrhea after starting Mounjaro is common and usually manageable with diet, hydration, and patience. Skipping a dose should not be your first response—talk to your healthcare provider about any significant or persistent symptoms. If you ever feel your condition is life-threatening or you notice alarming signs (severe dehydration, blood in stool, intense pain), seek medical care immediately.
Remember to speak to a doctor about any concerns, especially if symptoms escalate or you’re considering dose changes. Your provider can tailor recommendations to keep you safe and help you get the most benefit from Mounjaro.
(References)
* Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. PMID: 30473097; PMCID: PMC6308032.
* Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
* Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. PMID: 34186022.
* Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ, SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. PMID: 34672967.
* Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. PMID: 35133415; PMCID: PMC8826179.
* Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17. PMID: 35579691; PMCID: PMC9112245.
* Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM, SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. PMID: 37385275.
* Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816. PMID: 39037780.
* Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025 Feb;178(2):199-217. doi: 10.7326/ANNALS-24-01590. Epub 2025 Jan 7. PMID: 39761578.
* Guo L, Dong X, Ma J, Liu M, Lu Y, Wang H, Li Q, Li L, Deng Y, Xu J. Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025 Dec;13(12):1015-1029. doi: 10.1016/S2213-8587(25)00248-7. Epub 2025 Oct 27. PMID: 41167231.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.